期刊文献+

羟苯磺酸钙与厄贝沙坦联合治疗早期糖尿病肾病的疗效观察 被引量:10

原文传递
导出
摘要 目的探讨羟苯磺酸钙和厄贝沙坦联合治疗早期糖尿病肾病的疗效。方法 50例早期糖尿病肾病患者随机均分为两组:羟苯磺酸钙和厄贝沙坦联合治疗组(A组)和单用厄贝沙坦组(B组)。测定两组治疗前后血压、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、尿白蛋白排泄率(UAER)及血清淀粉样蛋白A(SAA)水平的变化。结果与治疗前比较,治疗后A组血压、FBG、HbA1c、UAER、SAA水平均下降(P<0.05),B组血压、FBG、HbA1C均下降(P<0.05),但UAER、SAA水平下降不明显(P>0.05)。结论羟苯磺酸钙与厄贝沙坦联合治疗早期糖尿病肾病能有效减少尿蛋白的排出,可能与降低SAA水平有关。
出处 《江苏医药》 CAS 2015年第3期337-338,共2页 Jiangsu Medical Journal
  • 相关文献

参考文献7

二级参考文献20

共引文献20

同被引文献77

  • 1陆菊明,潘长玉.糖尿病肾病的流行病学和诊断标准[J].中华老年多器官疾病杂志,2002,1(3):163-165. 被引量:82
  • 2何新霞,韩卫红,薛燕,王红燕,王乐.血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂对糖尿病肾病患者肾功能的保护作用[J].中国慢性病预防与控制,2007,15(1):34-35. 被引量:18
  • 3Ye H,Bai X,Gao H,et al.Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy[J].J Diabetes Complications,2014,28(1):96-100.
  • 4Zhang X.Therapeutic effects of calcium dobesilate on diabetic nephropathy mediated through reduction of expression of PAI-1[J].Exp Ther Med,2013,5(1):295-299.
  • 5Wang C,Min C,Rong X,et al.Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy[J].Discov Med,2015,20(108):67-77.
  • 6Schutte E,Lambers Heerspink HJ,Lutgers HL,et al.Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy:A Post Hoc Analysis of the RENAAL(Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan)Study and IDNT(Irbesartan Diabetic Nephropathy Trial)[J].Am J Kidney Dis,2015,66(3):450-458.
  • 7McM ullan CJ,Lambers Heerspink HJ,Parving HH,et al.Visit-tovisit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2diabetes and nephropathy:a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial[J].Am J Kidney Dis,2014,64(5):714-722.
  • 8Hartner A,Cordasic N,Klanke B,et al.Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation,not of endoplasmic reticulum stress[J].Biochim Biophys Acta,2014,1842(4):558-565.
  • 9Lambers Heerspink HJ,Weldegiorgis M,Inker LA,et al.Estimated GFR decline as a surrogate end point for kidney failure:a post hoc analysis from the Reduction of End Points in Non-InsulinDependent Diabetes With the Angiotensin II Antagonist Losartan(RENAAL)study and Irbesartan Diabetic Nephropathy Trial(IDNT)[J].Am J Kidney Dis,2014,63(2):244-250.
  • 10Ros-Ruiz S,Aranda-Lara P,Fernndez JC,et al.High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy[J].Nefrologia,2012,32(2):187-196.

引证文献10

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部